Peoples Bancorp Inc. and Capital Bancorp, Inc. Announce Merger Agreement

Peoples Bancorp will acquire Capital Bancorp in an all-stock transaction valued at approximately $728.1 million, with Capital shareholders receiving 1.11 PEBO shares per CBNK share, or $43.75 per share based on Peoples' 20-day VWAP. The combined bank is expected to hold roughly $14 billion in assets, $10 billion in loans and $11 billion in deposits across more than 150 locations, while adding Capital's Washington, D.C./Baltimore commercial franchise and nationwide specialty lending businesses. Peoples expects the deal to be immediately accretive to 2027 estimated earnings before one-time costs, generate an approximately 20% pro forma return on average tangible common equity, and achieve tangible book value earnback in under three years. Closing is targeted for the first half of 2027, subject to shareholder and regulatory approvals.

Analysis

The exchange ratio creates a clean CBNK/PEBO merger-arbitrage framework: CBNK fair value is 1.11x PEBO, so the relevant signal is the gross spread to that implied value rather than either standalone price move. With a first-half 2027 close, an unusually wide spread may be justified by duration, thin liquidity and the fact that PEBO stock—not cash—carries the consideration risk. A long CBNK/short 1.11 PEBO hedge removes most market and regional-bank beta, leaving approval, completion and deal-term risk.

For PEBO, the market should not capitalize management's return and accretion targets until the S-4 discloses cost saves, marks, pro forma CET1/TCE and the earnings power of the specialty units. The key second-order issue is that consumer-credit, mortgage and government-guaranteed lending/servicing businesses introduce more volatile fee income and potentially higher regulatory/operational risk than a conventional community-bank acquisition; this can limit PEBO's valuation multiple despite nominal EPS accretion. Conversely, a successful integration could establish PEBO as an acquirer of niche fee platforms, increasing its strategic scarcity versus similarly sized regional banks.

Near term, expect CBNK to trade toward deal value while PEBO absorbs dilution and execution uncertainty. The 1-3 month catalyst is disclosure of credit marks, retention arrangements, cost-save assumptions and the regulatory timetable; the 6-18 month catalyst is actual deposit retention and specialty-platform profitability through integration. The thesis is falsified by material adverse credit migration, a pro forma capital ratio below management's stated operating buffer, conditions that constrain specialty lending, or PEBO weakness that erodes the all-stock consideration value.

Contrarian view: the headline accretion may be less investable than the optionality embedded in PEBO's shares. A sub-three-year tangible-book earnback is constructive only if it does not rely on optimistic revenue synergies; investors should value the transaction on hard expense saves and the durability of acquired deposits, not on cross-sell claims. If CBNK's deal spread remains narrow despite limited details, there is no compelling standalone arb return after financing and borrow costs.

Key Decisions for Investors

• Monitor, do not immediately chase, CBNK. Initiate a hedged long CBNK/short 1.11x PEBO position only if the annualized gross spread exceeds 10-12% after stock-borrow and financing costs; target spread compression into the S-4 filing over 1-3 months, with sizing constrained by CBNK liquidity.
• Keep PEBO neutral until management quantifies cost saves, purchase-accounting marks and pro forma CET1/TCE. Upgrade to long PEBO only if disclosed hard cost saves support the stated accretion without assuming revenue synergies and capital remains comfortably above peer operating levels; downside is multiple compression if specialty earnings prove volatile.
• On the merger call and subsequent S-4, specifically track OpenSky credit performance, mortgage-lock pipeline exposure, SBA servicing economics, deposit attrition assumptions and executive retention. Any deterioration in these items is a trigger to widen the arb hedge or exit CBNK exposure.
• Use KRE as a macro hedge only for residual regional-bank beta in an unhedged PEBO position; do not use it for the CBNK/PEBO pair, where ratio hedging is the more precise risk control through expected closing.